Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non–small-cell Lung Cancer: A Retrospective Study-Reference-Cited by-同舟云学术

Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non–small-cell Lung Cancer: A Retrospective Study

Published:2018-09 Issue:5 Volume:19 Page:e629-e645
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Bittoni Marisa A.,Arunachalam Ashwini,Li Haojie,Camacho Ramon,He Jinghua,Zhong Yichen,Lubiniecki Gregory M.,Carbone David P.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. Non–small-cell lung cancer: role of the immune system and potential for immunotherapy;Carbone;J Thorac Oncol,2015

2. Incremental innovation and progress in advanced squamous cell lung cancer: current status and future impact of treatment;Langer;J Thorac Oncol,2016

3. Molecularly targeted therapies in non–small-cell lung cancer annual update 2014;Morgensztern;J Thorac Oncol,2015

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4/6 Inhibitor Efficacy in ESR1 -Mutant Metastatic Breast Cancer;NEJM Evidence;2024-04-23

2. Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling;Journal of the National Comprehensive Cancer Network;2024-01

3. Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland;Swiss Medical Weekly;2023-01-30

4. Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer;Cancer Medicine;2023-01-18

5. Prognostic factors of survival in patients with non-small cell lung cancer: a competing risk model using the SEER database;Translational Cancer Research;2022-11